Plain-English translation of NCT06222580 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing whether (SNDX-5613) combined with can safely and effectively treat a type of aggressive blood cancer called acute myeloid leukemia that hasn't responded to standard treatments. The trial focuses on patients whose cancer has specific genetic changes that make these two medications potentially helpful. Researchers will watch closely to understand how well this medication combination works and what side effects it causes.
Many patients with this type of blood cancer don't respond well to standard treatments, leaving them with very few options. This trial is designed to see if attacking the cancer using two different approaches at once—targeting two specific genetic pathways in the leukemia cells—might help patients who have run out of other choices.
You likely qualify if…
You likely don't qualify if…
You would take two pills by mouth each day (one medication twice daily, one once daily) for 28 days in a repeating cycle, continuing as long as the treatment is working and you are tolerating it well. You would have regular blood tests, bone marrow biopsies, heart imaging tests, and clinic visits to monitor how you're responding and check for any side effects. After you finish the medication, you would return for a follow-up visit at 30 days and then every 6 months for up to 2 years.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States